108 research outputs found

    Wilson's disease: update on pathogenesis, biomarkers and treatments

    Get PDF
    Wilson’s disease is an autosomal–recessive disorder of copper metabolism caused by mutations in ATP7B and associated with neurological, psychiatric, ophthalmological and hepatic manifestations. Decoppering treatments are used to prevent disease progression and reduce symptoms, but neurological outcomes remain mixed. In this article, we review the current understanding of pathogenesis, biomarkers and treatments for Wilson’s disease from the neurological perspective, with a focus on recent advances. The genetic and molecular mechanisms associated with ATP7B dysfunction have been well characterised, but despite extensive efforts to identify genotype–phenotype correlations, the reason why only some patients develop neurological or psychiatric features remains unclear. We discuss pathological processes through which copper accumulation leads to neurodegeneration, such as mitochondrial dysfunction, the role of brain iron metabolism and the broader concept of selective neuronal vulnerability in Wilson’s disease. Delayed diagnoses continue to be a major problem for patients with neurological presentations. We highlight limitations in our current approach to making a diagnosis and novel diagnostic biomarkers, including the potential for newborn screening programmes. We describe recent progress in developing imaging and wet (fluid) biomarkers for neurological involvement, including findings from quantitative MRI and other neuroimaging studies, and the development of a semiquantitative scoring system for assessing radiological severity. Finally, we cover the use of established and novel chelating agents, paradoxical neurological worsening, and progress developing targeted molecular and gene therapy for Wilson’s disease, before discussing future directions for translational research

    Distinctive Role of KV1.1 Subunits in the Biology and Functions of Low Threshold K+ Channels with Implication for Neurological Disease

    Get PDF
    This document is the Accepted Manuscript version of the following article: Saak V. Ovsepian; Marie LeBerre; Volker Steuber; Valerie B. O’Leary; Christian Leibold; & J. Oliver Dolly; ‘Distinctive role of KV1.1 subunit in the biology and functions of low threshold K+ channels with implications for neurological disease’, Pharmacology & Therapeutics, Vol. 159, March 2016, pp. 93-101. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ The version of record is available on line at doi: http:dx.doi.org/10.1016/j.pharmthera.2016.01.005 © 2016 Elsevier Inc. All rights reserved.The diversity of pore-forming subunits of KV1 channels (KV1.1–KV1.8) affords their physiological versatility and predicts a range of functional impairments resulting from genetic aberrations. Curiously, identified so far human neurological conditions associated with dysfunctions of KV1 channels have been linked exclusively to mutations in the KCNA1 gene encoding for the KV1.1 subunit. The absence of phenotypes related to irregularities in other subunits, including the prevalent KV1.2 subunit of neurons is highly perplexing given that deletion of the corresponding kcna2 gene in mouse models precipitates symptoms reminiscent to those of KV1.1 knockouts. Herein, we critically evaluate the molecular and biophysical characteristics of the KV1.1 protein in comparison with others and discuss their role in the greater penetrance of KCNA1 mutations in humans leading to the neurological signs of episodic ataxia type 1 (EA1). Future research and interpretation of emerging data should afford new insights towards a better understanding of the role of KV1.1 in integrative mechanisms of neurons and synaptic functions under normal and disease conditionsPeer reviewedFinal Accepted Versio

    Bioavailable Trace Metals in Neurological Diseases

    Get PDF
    Medical treatment in Wilson’s disease includes chelators (d-penicillamine and trientine) or zinc salts that have to be maintain all the lifelong. This pharmacological treatment is categorised into two phases; the first being a de-coppering phase and the second a maintenance one. The best therapeutic approach remains controversial, as only a few non-controlled trials have compared these treatments. During the initial phase, progressive increase of chelators’ doses adjusted to exchangeable copper and urinary copper might help to avoid neurological deterioration. Liver transplantation is indicated in acute fulminant liver failure and decompensated cirrhosis; in cases of neurologic deterioration, it must be individually discussed. During the maintenance phase, the most important challenge is to obtain a good adherence to lifelong medical therapy. Neurodegenerative diseases that lead to a mislocalisation of iron can be caused by a culmination of localised overload (pro-oxidant siderosis) and localised deficiency (metabolic distress). A new therapeutic concept with conservative iron chelation rescues iron-overloaded neurons by scavenging labile iron and, by delivering this chelated metal to endogenous apo-transferrin, allows iron redistribution to avoid systemic loss of iron

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    Biomarkers in motor neuron disease: A state of the art review

    Get PDF
    Motor neuron disease can be viewed as an umbrella term describing a heterogeneous group of conditions, all of which are relentlessly progressive and ultimately fatal. The average life expectancy is 2 years, but with a broad range of months to decades. Biomarker research deepens disease understanding through exploration of pathophysiological mechanisms which, in turn, highlights targets for novel therapies. It also allows differentiation of the disease population into sub-groups, which serves two general purposes: (a) provides clinicians with information to better guide their patients in terms of disease progression, and (b) guides clinical trial design so that an intervention may be shown to be effective if population variation is controlled for. Biomarkers also have the potential to provide monitoring during clinical trials to ensure target engagement. This review highlights biomarkers that have emerged from the fields of systemic measurements including biochemistry (blood, cerebrospinal fluid, and urine analysis); imaging and electrophysiology, and gives examples of how a combinatorial approach may yield the best results. We emphasize the importance of systematic sample collection and analysis, and the need to correlate biomarker findings with detailed phenotype and genotype data

    Etude IRMf de la plasticité cérébrale des réseaux moteurs et cognitifs dans la Sclérose Latérale Amyotrophique

    No full text
    In this work we used motor and cognitive tasks in an fMRI study to explore the early cortical reorganizations of the motor and extra-motor circuits in ALS patients. In a first part, using a simple motor task, we demonstrated (1) that increased cortical BOLD signal changes occurred in specific regions of the brain of ALS patients when their motor deficit was still moderate, and that this early signal changes correlated with (2) the lateralisation of the motor deficit or hand predominance and, more importantly, (3) with the rate of disease progression at one year and survival time, suggesting that modulations of cerebral activity in ALS may have functional implications. Furthermore, (4) this brain plasticity was maintained with time and disease progression during at least eleven months. In a second part, we demonstrated during a silent verbal fluency task (1) that ALS patients presented initially an increased cortical activation of areas devolved to the semantic process with an intensification of the functional network connectivity (FNC). (2) After eleven months and while their performance in tests of verbal fluency was stable, this cerebral compensation ran out with a decrease of the previous cerebral activations and the FNC. A N-back working memory paradigm, realized while the patients did not present any deficit of their working memory, allowed us to show that certain non-motor circuits were reorganized prematurely while patients were still asymptomaticCe travail a porté sur les remaniements corticaux précoces des circuits moteurs et extramoteurs dans la SLA grâce à l’étude des activations IRMf issues de tâches motrices et cognitives. La première partie de nos travaux nous a permis de montrer grâce des tâches simples d’activation motrice en IRMf (1) qu’alors que les patients SLA présentaient un déficit moteur discret, une augmentation des activations corticales est apparue dans les aires sensorimotrices bilatérales du cerveau. (2) Ces modifications précoces de l’activité neuronale étaient corrélées à la latéralisation du déficit moteur du membre ou la prédominance manuelle et surtout, (3) au taux de progression de la maladie à un an et à la survie, suggérant que ce remaniement de l’activité qui correspond probablement à de la plasticité cérébrale a des implications fonctionnelles. Enfin, (4) ce phénomène apparaissait actif puisqu’il s’est poursuivi pendant au moins onze mois. Dans la deuxième partie, nous avons montré lors d’une tâche de fluence verbale silencieuse que (1) les SLA présentaient une suractivation initiale des aires dévolues au processus sémantique avec un renforcement de la connectivité fonctionnelle entre les réseaux (CFR). (2) Au bout de onze mois et alors que l’atteinte des fluences était stable, ce phénomène de compensation s’épuisait avec une diminution conjointe de l’activation des réseaux et de la CFR. La tâche de 2-Back, réalisée alors que les patients ne présentaient pas d’atteinte de la mémoire de travail lors des tests psychométriques, nous a permis de montrer en outre que certains circuits non-moteurs se réorganisaient très précocement chez les patients, alors même qu’ils étaient asymptomatique

    fMRI study of cerebral plasticity of motor and cognitive networks in Amyotrophic Lateral Sclerosis

    No full text
    Ce travail a porté sur les remaniements corticaux précoces des circuits moteurs et extramoteurs dans la SLA grâce à l’étude des activations IRMf issues de tâches motrices et cognitives. La première partie de nos travaux nous a permis de montrer grâce des tâches simples d’activation motrice en IRMf (1) qu’alors que les patients SLA présentaient un déficit moteur discret, une augmentation des activations corticales est apparue dans les aires sensorimotrices bilatérales du cerveau. (2) Ces modifications précoces de l’activité neuronale étaient corrélées à la latéralisation du déficit moteur du membre ou la prédominance manuelle et surtout, (3) au taux de progression de la maladie à un an et à la survie, suggérant que ce remaniement de l’activité qui correspond probablement à de la plasticité cérébrale a des implications fonctionnelles. Enfin, (4) ce phénomène apparaissait actif puisqu’il s’est poursuivi pendant au moins onze mois. Dans la deuxième partie, nous avons montré lors d’une tâche de fluence verbale silencieuse que (1) les SLA présentaient une suractivation initiale des aires dévolues au processus sémantique avec un renforcement de la connectivité fonctionnelle entre les réseaux (CFR). (2) Au bout de onze mois et alors que l’atteinte des fluences était stable, ce phénomène de compensation s’épuisait avec une diminution conjointe de l’activation des réseaux et de la CFR. La tâche de 2-Back, réalisée alors que les patients ne présentaient pas d’atteinte de la mémoire de travail lors des tests psychométriques, nous a permis de montrer en outre que certains circuits non-moteurs se réorganisaient très précocement chez les patients, alors même qu’ils étaient asymptomatiquesIn this work we used motor and cognitive tasks in an fMRI study to explore the early cortical reorganizations of the motor and extra-motor circuits in ALS patients. In a first part, using a simple motor task, we demonstrated (1) that increased cortical BOLD signal changes occurred in specific regions of the brain of ALS patients when their motor deficit was still moderate, and that this early signal changes correlated with (2) the lateralisation of the motor deficit or hand predominance and, more importantly, (3) with the rate of disease progression at one year and survival time, suggesting that modulations of cerebral activity in ALS may have functional implications. Furthermore, (4) this brain plasticity was maintained with time and disease progression during at least eleven months. In a second part, we demonstrated during a silent verbal fluency task (1) that ALS patients presented initially an increased cortical activation of areas devolved to the semantic process with an intensification of the functional network connectivity (FNC). (2) After eleven months and while their performance in tests of verbal fluency was stable, this cerebral compensation ran out with a decrease of the previous cerebral activations and the FNC. A N-back working memory paradigm, realized while the patients did not present any deficit of their working memory, allowed us to show that certain non-motor circuits were reorganized prematurely while patients were still asymptomati

    Circuits de traitement du signal réalisables en technologie intégrée

    No full text
    corecore